13.07.2015 14:24:55
|
Blueprint Receives FDA Nod To Proceed With Clinical Trials For 2 Drug Candidates
(RTTNews) - Blueprint Medicines (BPMC) Monday said the U.S. Food and Drug Administration accepted the company's Investigational New Drug applications to begin Phase 1 clinical trials for its two lead drug candidates: BLU-554 and BLU-285.
BLU-554 is for the treatment of advanced hepatocellular carcinoma or HCC and cholangiocarcinoma, and BLU-285 is for unresectable, treatment-resistant gastrointestinal stromal tumor or GIST.
Blueprint is also on track to file an IND for BLU-285 in systemic mastocytosis.
BLU-554 is a potent and selective inhibitor of fibroblast growth factor receptor 4 or FGFR4. Aberrant signaling of FGFR4 is a disease driver in up to 30 percent of HCC patients. It may also play a role in a subset of patients with cholangiocarcinoma, a related cancer of the biliary duct.
HCC is the most prevalent form of liver cancer. Liver cancer is the second-leading cause of cancer-related deaths worldwide.
BLU-285 is a potent and selective inhibitor of KIT Exon 17 and PDGFR-alpha D842V mutants, which are key disease drivers of metastatic and treatment-resistant GIST, which is the most common form of sarcoma of the gastrointestinal tract.
Patients with the KIT Exon 17 and PDGFR-alpha D842V mutants are not adequately treated with existing therapies.

Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Blueprint Medicines Corpmehr Nachrichten
12.02.25 |
Ausblick: Blueprint Medicines legt Zahlen zum jüngsten Quartal vor (finanzen.net) | |
29.10.24 |
Ausblick: Blueprint Medicines stellt Ergebnisse des abgelaufenen Quartals vor (finanzen.net) |
Analysen zu Blueprint Medicines Corpmehr Analysen
Aktien in diesem Artikel
Blueprint Medicines Corp | 87,68 | -2,06% |
|